Miles International Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Miles International Pharmaceutical Export Portfolio Dataset — 4 Products, $268.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Miles International — Pharmaceutical Exporter Profile (2026) | 4 Products, $268.6K Trade | TransData Nexus

Miles International

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $268.6K Total Trade · DGFT Verified

Miles International is an Indian pharmaceutical exporter with a total trade value of $268.6K across 4 products in 1 therapeutic categories. Based on 63 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Bortezomib ($129.4K), Cetuximab ($51.5K), Daratumumab ($49.2K).

Miles International — Export Portfolio & Destination Treemap

Miles International pharmaceutical export portfolio — 4 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Miles International? — Company Overview & Market Position

Miles International, established in 2002, is a Mumbai-based pharmaceutical trading company specializing in the export and import of branded and generic medicines. The company has been supplying products to regions including Latin America, the Caribbean, Eastern Europe, and North Africa. Miles International is recognized for its commitment to quality, competitive pricing, and comprehensive services.

The company's product portfolio encompasses generic drugs, branded pharmaceuticals, and over-the-counter (OTC) health and beauty products. Miles International also offers specialized services such as cold chain management, drop shipments, and parallel imports. The firm's suppliers include prominent pharmaceutical manufacturers like Sun Pharma, Cipla, Alkem Laboratories, Natco, Naprod, Khandelwal Laboratories, and Serum Institute of India.

What Does Miles International Export? — Product Portfolio Analysis

Top Products by Export Value

1Bortezomib$129.4K 2Cetuximab

Product Portfolio — Top 4 by Export Value

Miles International exports 4 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Bortezomib	Advanced Oncology	$129.4K	28	0.6%	13
2	Cetuximab	Advanced Oncology	$51.5K	12	6.1%	2
3	Daratumumab	Advanced Oncology	$49.2K	17	3.7%	10
4	Dacarbazine	Advanced Oncology	$38.5K	6	2.7%	10

Miles International exports 4 pharmaceutical products across 1 therapeutic categories with a total export value of $268.6K. The top category is Advanced Oncology (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Miles International — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Miles International operates as a pharmaceutical trading company and does not own manufacturing facilities. Instead, it collaborates with established pharmaceutical manufacturers to source its products. The company emphasizes adherence to Good Distribution Practices (GDP) and Good Manufacturing Practices (GMP) to ensure product quality and safety.

3Key Leadership

The Managing Director of Miles International is Brajesh Sahaya, who has been instrumental in the company's growth and strategic direction. Under his leadership, the company has expanded its operations and product offerings, focusing on quality and customer satisfaction.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Miles International Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Miles International's export activities are primarily focused on regions such as Latin America, the Caribbean, Eastern Europe, and North Africa. The company has established a reputation for supplying quality medicines at competitive prices and has been supplying products to these regions since 2006. While specific regulatory approvals in the US, EU, UK, Australia, and Japan are not detailed in the available sources, the company's adherence to international standards suggests a commitment to meeting regulatory requirements in these markets.

2Emerging Markets

Miles International has a significant presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's focus on supplying quality medicines to these regions aligns with the World Health Organization's prequalification program, which aims to ensure the quality, safety, and efficacy of medical products.

3Geographic Strategy

Miles International's geographic strategy involves focusing on regions such as Latin America, the Caribbean, Eastern Europe, and North Africa. This targeted approach allows the company to concentrate its resources and expertise, reducing concentration risk and enhancing its market presence in these areas.

Miles International — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

As a pharmaceutical trading company, Miles International does not manufacture products but sources them from established pharmaceutical manufacturers. Therefore, the company does not have FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, or inspection history. However, the company emphasizes adherence to international standards, including Good Distribution Practices (GDP) and Good Manufacturing Practices (GMP), to ensure product quality and safety.

2WHO & EU GMP

Miles International emphasizes adherence to international standards, including Good Distribution Practices (GDP) and Good Manufacturing Practices (GMP), to ensure product quality and safety. The company's suppliers are expected to comply with these standards, aligning with the World Health Organization's guidelines for the distribution and manufacturing of pharmaceutical products.

3CDSCO & Indian Regulatory

As a pharmaceutical trading company, Miles International sources products from various manufacturers. While specific details regarding the company's compliance with the Central Drugs Standard Control Organization (CDSCO) regulations, state drug controller approvals, and export No Objection Certificates (NOCs) are not provided in the available sources, the company's emphasis on adhering to international standards suggests a commitment to meeting regulatory requirements in India.

Miles International — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Miles International operates in a competitive landscape with several key players in the pharmaceutical trading industry. While specific market share comparisons are not available, the company's focus on quality, competitive pricing, and comprehensive services positions it as a strong competitor in its target markets.

2Key Differentiators

Miles International's key differentiators include its commitment to quality, competitive pricing, and comprehensive services such as cold chain management, drop shipments, and parallel imports. The company's emphasis on adhering to international standards, including Good Distribution Practices (GDP) and Good Manufacturing Practices (GMP), further distinguishes it in the market.

3Strategic Position

Miles International's current strategic direction focuses on supplying quality medicines to regions such as Latin America, the Caribbean, Eastern Europe, and North Africa. The company's future outlook includes leveraging its widespread network of customers to proactively benefit from synergistic opportunities with global collaborators, aiming for continued growth and expansion in the pharmaceutical trading industry.

Buyer Due Diligence Brief — Evaluating Miles International as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Miles International has established strong relationships with a diverse supplier base, including prominent pharmaceutical manufacturers like Sun Pharma, Cipla, Alkem Laboratories, Natco, Naprod, Khandelwal Laboratories, and Serum Institute of India. The company's emphasis on adhering to international standards, including Good Distribution Practices (GDP) and Good Manufacturing Practices (GMP), indicates a reliable and consistent track record in sourcing and supplying pharmaceutical products.

2Certifications to Verify

Importers should verify the following certifications when sourcing from Miles International:

FDA Approval: To ensure compliance with U.S. regulatory standards.

WHO-GMP Certification: To confirm adherence to the World Health Organization's Good Manufacturing Practices.

EU GMP Certification: To verify compliance with European Union Good Manufacturing Practices.

Frequently Asked Questions — Miles International

How many pharmaceutical products does Miles International export from India?

Miles International exports 4 pharmaceutical products across 1 therapeutic categories. The top exports are Bortezomib ($129.4K), Cetuximab ($51.5K), Daratumumab ($49.2K), Dacarbazine ($38.5K). Total export value is $268.6K.

What is Miles International's total pharmaceutical export value?

Miles International's total pharmaceutical export value is $268.6K, based on 63 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Miles International cover?

Miles International exports across 1 therapeutic categories. The largest are Advanced Oncology (100.0%, 4 products).

Get Full Miles International Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.